Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 31, 2026
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
View original at finance.yahoo.comAptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights Aptose Biosciences, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Shareholders have approved the proposed arrangement with Hanmi, which enables continued and expanded development of the TUS+VEN+AZA triplet
60% confidenceThe clinical trial data continue to support the promise of TUS+VEN+AZA therapy
60% confidenceTUS+VEN+AZA triplet has shown promising response rates and safety as a mutation agnostic therapy across a diverse population of patients newly diagnosed with AML
60% confidenceTUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations
60% confidence
Cited in these Via News reports
- AI-Designed Antibody BD200 Outperforms Standard Treatments in Drug-Resistant Cancers, Marking First Clinical Trial for Machine Learning Platform →
- Amgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research Strategy →
- Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals →